Close Menu

NEW YORK (GenomeWeb) – Personal Genome Diagnostics said today that it is moving forward with the development of a novel diagnostic to help identify which cancer patients are most likely to benefit from treatment with immune checkpoint inhibitors under an SBIR contract awarded by the National Institutes of Health late last year.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
26

As new variants of SARS-CoV-2 circulate around the globe, there is growing concern among clinical laboratories that these variants may impact their ability to accurately detect the virus.